Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial

Posted on by

Lancet Respiratory Medicine
Feb 2022 Volume 10 Number 2 p121-220, e11-e24
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial
Aurélien Mazeraud,et al.